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Mutation of the human genome ranges from single base-pair changes to whole-chromosome aneuploidy. Karyo-
typing, ﬂuorescence in situ hybridization, and comparative genome hybridization are currently used to detect
chromosome abnormalities of clinical signiﬁcance. These methods, although powerful, suffer from limitations in
speed, ease of use, and resolution, and they do not detect copy-neutral chromosomal aberrations—for example,
uniparental disomy (UPD). We have developed a high-throughput approach for assessment of DNA copy-number
changes, through use of high-density synthetic oligonucleotide arrays containing 116,204 single-nucleotide poly-
morphisms, spaced at an average distance of 23.6 kb across the genome. Using this approach, we analyzed samples
that failed conventional karyotypic analysis, and we detected ampliﬁcations and deletions across a wide range of
sizes (1.3–145.9 Mb), identiﬁed chromosomes containing anonymous chromatin, and used genotype data to de-
termine the molecular origin of two cases of UPD. Furthermore, our data provided independent conﬁrmation for
a case that had been misinterpreted by karyotype analysis. The high resolution of our approach provides more-
precise breakpoint mapping, which allows subtle phenotypic heterogeneity to be distinguished at a molecular level.
The accurate genotype information provided on these arrays enables the identiﬁcation of copy-neutral loss-of-
heterozygosity events, and the minimal requirement of DNA (250 ng per array) allows rapid analysis of samples
without the need for cell culture. This technology overcomes many limitations currently encountered in routine
clinical diagnostic laboratories tasked with accurate and rapid diagnosis of chromosomal abnormalities.
Introduction
Chromosome abnormalities are associated with a wide
range of clinical problems, from cancer to abnormal mor-
phological and neurological development in neonates,
children, and adolescents. The identiﬁcation and char-
acterization of chromosome abnormalities represent the
cornerstone of cytogenetic analysis and are crucial for
the accurate diagnosis and prognosis of associated clini-
cal disorders. Current methods used for assessing chro-
mosomal integrity and copy number focus on micros-
copy of metaphase chromosome spreads and interphase
nuclear preparations; these techniques include karyotyp-
ing and FISH. Despite the great diagnostic and prognos-
tic beneﬁts provided by these methods, microscopy has
several obvious shortcomings. First, resolution is limited
to large ampliﬁcations, deletions, and translocations of
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3–5 Mb and greater. Second, preparation of chromo-
some spreads requires cell cultures, which can take sev-
eral weeks, and is often unsuccessful in biopsy samples
from patients with cancer (Mandahl 1992). The ever-
increasing catalogue of microdeletions and duplications
associated with speciﬁc single-gene disorders and clini-
cal syndromes indicates that there is a complete spec-
trum of copy-number mutation sizes, with a range from
very large to potentially very small (Sellner and Taylor
2004). Other comparative genomic hybridization (CGH)
approaches to genomewide detection of copy-number
changes use a large number of discrete genomic or cDNA
clones in arrays (array-based CGH) (Kallioniemi et al.
1992; Albertson et al. 2000; Hodgson et al. 2001; Snij-
ders et al. 2001; Pollack et al. 2002; Ishkanian et al.
2004). Several limitations of these CGH arrays include
the need for large amounts of starting material, resolu-
tion limited by the number of clones that can be depos-
ited on the arrays, reagent variability from site to site,
and lack of manufacturing standards; all of these con-
straints make it difﬁcult for individual laboratories to
conduct reproducible experiments. Therefore, an easy,
rapid, and robust technology capable of identifying ge-
nomewide aberrations at ultrahigh resolutionwould rep-
resent an important advance in clinical diagnostics.
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Table 2
Summary of Quantitative Fluorescence PCR
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 1 Analysis of Mapping 100K data with use of CNAT. Patient C1 is shown, with the 1.5-Mb deleted region on chromosome
7p14.1-14.2 indicated by vertical lines. Chromosomal position (in Mb) is indicated on the X-axis for all three panels. Estimated copy-number
changes are shown in the upper panel, P values are shown in the middle panel, and the LOH score is shown on the bottom panel. The default
window size of 0.5 Mb was used.
High-density synthetic oligonucleotide microarrays
have been developed for the ability to access large quan-
tities of genetic information in a single experiment (Fo-
dor et al. 1991, 1993; Pease et al. 1994). These arrays
have been used extensively to measure RNA transcripts
(reviewed by Kapranov et al. [2003]), to resequenceDNA
(Warrington et al. 2002), and to accurately genotype
thousands of SNPs (Kennedy et al. 2003), all with use
of simple biochemical target preparation methods and
minimal instrumentation.
The principle of using high-density SNP genotyping
arrays for DNA copy-number analysis has been demon-
strated elsewhere, ﬁrstwith arrays containing 1,494SNPs
and, subsequently, with arrays containing 11,555 SNPs.
The majority of these studies have focused on cancers
(Lindblad-Toh et al. 2000; Primdahl et al. 2002; Schu-
bert et al. 2002; Dumur et al. 2003; Hoque et al. 2003;
Lieberfarb et al. 2003; Bignell et al. 2004; Huang et al.
2004; Janne et al. 2004; Paez et al. 2004; Wang et al.
2004; Wong et al. 2004; Zhou et al. 2004a, 2004b),
but a recent report used microarrays with 11,555 SNPs
to study constitutional copy-number changes in men-
tally retarded individuals (Rauch et al. 2004). Such ar-
rays not only provide SNP genotypes at 199.5% accu-
racy, but they also utilize quantitative hybridization sig-
nal intensities to estimate copy-number changes, such as
ampliﬁcations and deletions (Bignell et al. 2004; Huang
et al. 2004). In addition, the approach of combining
genotypes and copy-number estimation allows the de-
tection of regions of loss of heterozygosity (LOH) with
or without copy-number change (Zhao et al. 2004).
Rapid advances in high-density SNP genotyping tech-
nology have resulted in the recent development of com-
mercially available arrays, Affymetrix GeneChip 100K
mapping arrays, that contain 116,204 genomewide SNPs
(Matsuzaki et al. 2004b). The mean and median inter-
SNP distances of this set are 23.6 kb and 8.5 kb, re-
spectively. Over 99% of the genome is within 500 kb of
a SNP (i.e., 0.5 Mb), and 91% of the genome is within
100 kb of a SNP (Matsuzaki et al. 2004a); this provides
the capability of assessing copy-number changes at an
unprecedented resolution. The 100K mapping array se-
lects against SNPs in segmental duplications because it
selects SNPs on the basis of genotyping accuracy, robust-
ness, Mendelian inheritance, Hardy-Weinberg equilib-
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Table 3
Summary of Family Data on Chromosome 15
FAMILY, SPECIFIC RELATED DISORDER,
AND SNP INTERVAL
NO.
OF
SNPS
GENOTYPE CONCORDANCE
ON CHROMOSOME 15
(%)
Child vs. Mother Child vs. Father
F1:
Maternal uniparental isodisomy 15:
SNP_A-1713638–SNP_A-1708745 87 72.8 62.2
SNP_A-1753891–SNP_A-1715425 2,945 100 64
SNP_A-1713638–SNP_A-1715425 3,032 99.2 64.0
F2:
Maternal uniparental heterodisomy 15:
SNP_A-1713638–SNP_A-1715425 3,032 100 63.6
NOTE.—SNP and concordance information was determined by the GeneChip 100K map-
ping arrays. The 46,XY,upd(15)mat alteration was identiﬁed by microsatellites.
Table 4
Five-Value Summary of Patient Data
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
rium, duplicates, and reproducibility (H.Matsuzaki, per-
sonal communication).
Here, we describe the application of 100K mapping
arrays for detection of clinically signiﬁcant cytogenetic
abnormalities, both constitutional and acquired. Nota-
bly, the resolution of these arrays permits detection of
submicroscopic copy-number abnormalities.
Material and Methods
Clinical Cases
All clinical cases were referred for routine cytogenetic
analysis—by obstetric, pediatric, or neurology special-
ists—by use of stored DNA. The study complied with
internal ethics committee requirements. Our sample
population consisted of 23 individuals, 17 with known
cytogenetic abnormalities, including unbalanced, struc-
tural, and whole-chromosome abnormalities (table 1).
The raw genotypes for all patients in this study are in-
cluded in a tab-delimited ASCII ﬁle (online only) that
can be imported into a spreadsheet. In some cases, char-
acterization was incomplete because of the limitations
of conventional analysis or lack of patient material.
100K Mapping Arrays
The Mapping 100K Set comprises two arrays (one
uses XbaI, and the other, HindIII restriction enzymes),
each with 150,000 SNPs (XbaI has 58,960 SNPs, and
HindIII has 57,244 SNPs, for a total of 116,204 SNPs).
The spacing of the SNPs on these arrays indicates that
99.1% of the genome is within 500 kb of a SNP, 91.6%
is within 100 kb, and 40% is within 10 kb (Matsuzaki
et al. 2004a). These calculations exclude centromeres,
telomeres, and heterochromatin, which account for 0.226
Gb (total genome Gb; after removal ofsizep 3.069
these large gaps, the effective genome Gb).sizep 2.843
The largest span between SNPs (4.9 Mb) is on the X
chromosome.
Data Analysis
Genotype calls were determined usingGeneChipDNA
Analysis software (GDAS). Copy-number estimations
were determined using the CHP ﬁle output from GDAS
andGeneChip ChromosomeCopyNumberAnalysis Tool
(CNAT), which is available, free of charge, for download
at the Affymetrix Web site. CNAT implements an algo-
rithm that uses genotype information and signal-probe
intensities to calculate copy-number changes that are
based on SNP hybridization signal-intensity data from
the experimental sample relative to intensity distribu-
tions derived from a set of 100 normal reference indi-
viduals (Huang et al. 2004). The log of the arithmetic
average of the perfect match (PM) intensities across 20
probes (S) is used as the basic measurement for any given
SNP.
201
Sp log PM . i( )20 ip1
After S is calculated, it is scaled to have a mean of 0
and a variance of 1 for all autosomal SNPs, to decrease
the variability across samples. Sample normalization is
done across all features on the array,
`S  mi
˜S p ,i
jˆ
J1
mp S , jJ jp1
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Table 5
Five-Value Summary of 42 White Reference Samples
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 6
Medians and 95% CIs for Patient Samples
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
and
J12
ˆ ˆ( )j p S  m , j jJ 1 jp1
where J is the number of SNPs.
To determine the signiﬁcance of a copy-number change
for a speciﬁc SNP, the signal-intensity variation of the
SNP across a set of normal samples is determined. The
statistics are calculated for each genotype of SNP, with
allowance for genotype dependencies in the statistics.
The mean and variance are estimated across the normal
samples,
Kg1
˜m p S (k)jg jgK kp1g
and
Kg1 22 ˜j p S (k) m ,[ ]jg jg jgK  1 kp1g
where are the normal samples with thekp 1,…Kg
same genotype, . The normalized in-gp (AA,BB,AB)
tensity for the SNP is compared with the expected in-
tensity for , as determined by the log intensityCNp 2
of the SNP in the reference set, with use of the copy-
number (CN) response curve determined from dosage
response data,
`logCNp a b(S m ) ,jg
where and forMapping 50KXbaIap 0.658 bp 0.714
and and forMapping 50KHindIII.ap 0.638 bp 0.703
This corresponds to the single-point-analysis copy num-
ber (SPA_CN). The signiﬁcance of the copy-number var-
iation (CNV) is estimated by comparison with the ref-
erence set. For each SNP, separate statistics are derived
for each genotype in the reference set,

˜ `S  m 2 2j jg tp p 0.5# erfc erfc(x)p e dt ,j ( ) ˆ2j pjg
x
so comparisons are made with samples sharing the same
genotype, for calculation of the probability that CNp
, known as the P value. We report the log P value.2
The larger the number, the less probable that the copy
number is equal to 2. If log P is very large, then it is
very unlikely that . A Gaussian kernel-smooth-CNp 2
ing average was also used for averaging the copy number
and P value of individual SNPs over a ﬁxed genomic
interval. The smoothing averages out the random noise
across neighboring SNPs and minimizes the false-posi-
tive rate (FPR), while keeping the true-positive rate high.
The kernel-smoothing accentuates genomic intervals in
which consecutive SNPs display the same type of altera-
tion (gain or loss). The default window size of 0.5 Mb
was used, unless otherwise indicated.
—
CN(j)p K(x  x )CN , i j i
i
z¯ p K(x  x )z ,j i j i
i
z¯jp p 0.5erfc ,j ( )2
21 x
K(x)p exp 0.5 ,( )[ ] a2pa
and
x p physical position of SNP .j j
In general, when analyzing an unknown sample, the rec-
ommended approach is to use the default window size
of 0.5 Mb, because of the spacing of the SNPs on these
arrays (99.1% of the genome is within 0.5 Mb). After
review of the initial data, a larger window may be ap-
propriate, if the detected aberration is signiﬁcantly larger
than the default window size. By increasing the window
size, the noise is reduced because of incorporation of
many more adjacent probes into the window. This is
advantageous only if all of the probes in the window are
expected to behave the same; that is, they have under-
gone the same aberration, such as a whole-chromosome
trisomy. It should be noted that a trisomy can be detected
using either the default window size or a larger window
size; the major difference is in the conﬁdence (P value)
associated with the trisomy. Both the copy number and
P values are smoothed. These smooth copy number and
P values are referred to as “GSA_CN” and “GSA_pVal,”
respectively.
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Table 7
Average Values for Aberrations Observed in Patient
Samples
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
The LOH score calculates the probability of being ho-
mozygous for each SNP from the reference ﬁle. If each
SNP is treated independently, then the probability of a
stretch of SNPs (position mrn) all being homozygous
can be calculated.
number of AA or BB calls on SNPj
Pp ,j total number of genotype calls on SNPj
n
P(SNP m r n homozygous)p P , j
jpm
and
LOHp  logP(SNP m r n homozygous) .
Regions of duplication and deletion are reported as the
ﬁrst and last SNP showing either (1) signiﬁcant increases
in copy number associated with a positive P value or (2)
decreased copy number, negative P value, and associated
LOH (table 1).
Original Identiﬁcation and Veriﬁcation Methods
FISH with use of BACs was performed on interphase
or metaphase chromosome preparations by standard
methods (Lichter and Cremer 1992). Multiplex ligation-
dependent probe ampliﬁcation (MLPA) assays were ob-
tained from MRC-Holland. The MLPA protocol has
been described in detail elsewhere (Schouten et al. 2002).
Quantitative genomic real-time PCR was performed as
a duplex PCR for the test exons labeled with FAM and
CFTR exon 24 (MIM 602421), used as an internal con-
trol and labeled with HEX. The HEX-labeled undeleted
control was also run as a duplex PCR with FAM-labeled
exons 2 and 5 from the APC gene (MIM 175100). The
TaqMan ﬂuorescent probes were synthesized in accor-
dance with the Applied Biosystems primer express soft-
ware program. The PCR protocol with use of the Plati-
num QPCR mix was performed in accordance with the
manufacturer’s instructions (Invitrogen). TheCt (thresh-
old cycle) value of the test probe and control probe are
compared and normalized using the method (Ap-(2DCt)2
plied Biosystems), where is the difference betweenDCt
the test and the control and is the difference be-2DCt
tween the value and the average of the normalDCt DCt
control samples. A ﬁnal “normalized value,” , of(2DCt)2
!0.5 is indicative of a deletion.
Results
We tested cases containing heterozygous deletions, du-
plications, whole-chromosome aneuploidy, other unbal-
anced rearrangements, and uniparental disomy (UPD)
(table 1). Most of these cases have been partly or fully
characterized elsewhere, with use of other techniques,
such as FISH andMLPA-PCR (Slater et al. 2003; Rooms
et al. 2004). In all cases, the physical position of each
deletion or duplication determined by SNP analysis was
consistent with the karyotype band location.
Analysis of Problematic Samples
Karyotyping suffers from the limitations of chromo-
some banding, sample preparation, and subjective analy-
sis. Common causes of unsuccessful or inaccurate cyto-
genetic testing are suboptimal quality of metaphase prep-
arations, inability to stimulate cell division in culture
(particularly troublesome in the testing of leukemic bone
marrows from children and necrotic products of con-
ception), and samples that contain inadequate numbers
of viable cells for processing.
Patient C1, a female with pediatric acute lymphocytic
leukemia (ALL), exempliﬁes several of the main advan-
tages of using the Mapping 100K approach for prob-
lematic samples. Bone marrow G-banded chromosome
preparations from this type of sample are typically very
poor and consequently allow, at best, only low-resolu-
tion (i.e., !400 bands) analysis. A complex karyotype
involving two abnormal clones—46,XX,del(11)(q23)[2]/
45,X,-X,del(11)(q23),inc[5]/46,XX[5]—was initially ob-
served. Of 300 cells analyzed using FISH, 81% showed
an apparent deletion of chromosome 11 at band q23,
which is clinically relevant because of the potential in-
volvement of the mixed-lineage leukemia gene (MLL
[MIM 159555]). Many cells contained only one X chro-
mosome; other abnormalities were suspected, but none
was clearly identiﬁable. The Mapping 100K arrays
showed a large 56.3-Mb terminal deletion of chromo-
some 11 at band q14.3 and a 30-Mb duplication of
chromosome X at band Xq25 (table 1). The array data
indicated that the breakpoint was at 11q14.3 rather than
11q23, which demonstrates that higher-resolution an-
alysis allows for more-accurate breakpoint determina-
tions (see below). Together with the Mapping 100K data,
reinterpretation of the karyotype is consistent with a
derivative that consists of chromosome 11 with a break-
point at q14.3 ligated to the distal region of Xq25-ter.
In addition, a small (1.5 Mb) deletion was found on
chromosome 7 at band p14.1-14.2, which is one of the
smallest deletions observed in the present study (ﬁg. 1)
and was not detected in the original analysis (table 1).
We veriﬁed this deletion, using quantitative real-time
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Figure 2 A, Duplication (1.4 Mb) at chromosome band 17p11.2 in patient B1: GeneChip Mapping 100K array proﬁles of copy-number
duplication (GSA_CN) and positive P value (GSA_pVal) on chromosome 17 (boxed section), with use of a 1.0-Mb window. X-axis indicates
chromosomal position (in Mb); Y-axes indicate estimated copy-number changes (upper panel), P values (middle panel), and LOH score (bottom
panel). B, FISH with use of BAC probe RP11-791M8, which contains the PMP22 gene, showing the duplication as an extra signal in interphase
nuclei.
PCR with two different sequences selected from exons
located within the deleted region, as well as control se-
quences located outside the deleted region (table 2). Pa-
tient C1 and four unaffected control samples were as-
sayed twice in triplicate. For probes within the deleted
region, the normalized values for patient C1 were !0.5
(0.21 and 0.23 for BC039725 and ELMO1, respec-
tively), which indicates a deletion. For probes outside
the deleted region, the normalized values for patient C1
were equal to 1.18 and 0.84 for APC exons 5 and 2,
respectively (table 3), which indicates no deletion. These
quantitative PCR results conﬁrm the small deletion ﬁrst
detected by GeneChip Mapping 100K arrays (ﬁg. 1).
Patient A1 contains a derivative of a maternal inser-
tion, ins(6;12)(p21.3;q22q23). There is an interstitial de-
letion on chromosome 12 involving bands q22 and q23
that was not detected in the original prenatal, 400-band,
G-banded metaphase preparations. A neonatal prepara-
tion was required to identify the abnormality in 600–
800 band preparations. The Mapping 100K array ap-
proach detected a 13.6-Mb deletion (table 1). The region
contains ∼111 genes, including phenylalanine hydrox-
ylase (PAH [MIM 261600]). Interestingly, this patient
exhibited a low-level increase in serum phenylalanine,
consistent with a single-copy deletion of PAH.
It should be noted that ﬁgure 1 also shows P values
similar to the known observed deletion. Since this study
was designed to determine whether the technology could
detect known copy-number changes in cytogenetic refer-
ral samples, cutoffs for signiﬁcance of novel abnormal-
ities were not determined. Without extensive validation
of cutoffs for signiﬁcance, we cannot assess a priori
whether these P values represent false-positive or true-
positive results. As an initial attempt to evaluate this
observed variation, we assumed that the bulk of the data
in any particular sample should follow the normal dis-
tribution of a copy number equal to 2 and a P value
equal to 0. In fact, the average copy number was 2.09,
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Figure 3 Analysis with use of Integrated Genome Browser (Affymetrix). A, GeneChip 100K array LOH proﬁles of chromosome 5, dem-
onstrating the subtle differences in size and location. Physical position is shown on the X-axis. The Y-axis shows LOH values from CNAT for
three different patient samples, with comparison of three deletions in chromosome 5 at band q14.2-q15 in patients A5, A6, andA7.B,Enlargement
of deleted regions, showing corresponding genome information. The gene MASS1 (circled) is located in the common region of overlap (boxed
section). The default window size of 0.5 Mb was used.
and the P value was 0.20 for the patients in this study
(tables 4 and 5), which indicates an overall excellent ﬁt
with these expected values. In addition, we hypothesized
that SNPs that fell outside the 95% CI should represent
true aberrations, since they are statistically different from
the overall “normal” distribution. For each of the ab-
errations described in table 1, we determined whether
these regions fell outside the 95% CI (tables 6 and 7).
Under this assumption, we determined the FPR to be
2.04%–3.48% (see appendix A).
Identiﬁcation of Small Deletions and Duplications
Aberrations !5 Mb in size are difﬁcult to detect by
conventional microscopic analysis. Patient A2 has an
interstitial deletion located on chromosome 17 at band
Figure 4 A, Deleted region (4.6 Mb) at chromosome band 17p12-p13.1 in patient A8: GeneChip Mapping 100K array proﬁles of copy-
number deletion (GSA_CN), negative P value (GSA_pVal), and LOH block on chromosome 17 (boxed section). The default window size of
0.5 Mb was used. X-axis indicates chromosomal position (in Mb); Y-axes indicate estimated copy-number changes (upper panel), P values
(middle panel), and LOH score (bottom panel). B, Metaphase FISH with use of BAC RP11-601N13, showing the deleted chromosome 17
(white arrow) and the normal chromosome 17 (black arrow) with ﬂuorescence signals.
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Figure 5 A, Duplication (7.7 Mb) at chromosome band 6p25 in patient B4: GeneChip Mapping 100K array proﬁles of copy-number
duplication (GSA_CN) and positive P value (GSA_pVal) on chromosome 6 (boxed section). The default window size of 0.5 Mb was used. X-
axis indicates chromosomal position (in Mb); Y-axes indicate estimated copy-number changes (upper panel), P values (middle panel), and LOH
score (bottom panel). B, Original karyotype showing larger chromosome 6, which was veriﬁed by metaphase FISHwith use of whole chromosome
6 paint, consistent with the p-arm duplication (white arrow) and normal chromosome 6 (black arrow).
p11.2 (table 1). It is speciﬁcally associated with the rela-
tively common condition known as “hereditary neurop-
athy with pressure palsies” (HNPP [MIM 162500]).
Mapping 100K arrays identiﬁed a region of 1.3Mb with
copy-number reduction and LOH. This region contains
the gene PMP22, which has been shown through haplo-
insufﬁciency to be responsible for the demyelination ob-
served in HNPP (Woodward and Malcolm 2001).
Patient B1 had the smallest duplication observedamong
the samples (1.4 Mb). This aberration is a submicro-
scopic, interstitial duplication on chromosome 17 at band
p11.2. This duplication is speciﬁcally associated with the
relatively common peripheral neuropathy, Charcot-Ma-
rie tooth disease, type 1A (CMT1A [MIM #118220]).
Mapping 100K arrays detected a region of increased copy
number that was indicative of segmental duplication (ta-
720 Am. J. Hum. Genet. 77:709–726, 2005
Figure 6 A, Trisomy 8: GeneChip Mapping 100K array proﬁles of copy-number duplication (GSA_CN) and positive P value (GSA_pVal)
on chromosome 8, with use of a 10-Mb window. B, Partial G-banded karyotype, showing three chromosome 8 homologues in patient C4. X-
axis indicates chromosomal position (in Mb); Y-axes indicate estimated copy-number changes (upper panel), P values (middle panel), and LOH
score (bottom panel).
ble 1 and ﬁg. 2a). Duplication of this region was con-
ﬁrmed by FISH (ﬁg. 2b). Because of the small size of the
aberrations, both of these very common genetic disorders
(incidence 1:2,500) are currently diagnosed through spe-
ciﬁc clinical referral for PCR or FISH, which require lo-
cus-speciﬁc probes. The 100K arrays offer a unique ad-
vantage, in that they can be used simultaneously as a
screening approach as well as to provide deﬁnitive down-
stream diagnostic capabilities.
High-Resolution Breakpoint Determination
The ability to better deﬁne the breakpoints of chromo-
somal aberrations provides more-accurate information
for clinical diagnosis. Patients A3 and A4 have intersti-
tial deletions in the same location on chromosome 15
at band q12, deletions that are associated speciﬁcally
with two different imprinting disorders, Prader-Willi
syndrome (PWS [MIM #176270]) and Angelman syn-
drome (AS [MIM #105830]), respectively. Through use
of the GeneChip Mapping 100K arrays, both deletions
and LOH were detected (table 1). Furthermore, the de-
letion for patient A4 was found to consist of two sepa-
rate but closely spaced regions, of 1.6 and 1.7 Mb (ta-
ble 1), with a copy number 12 and a P value 10, highly
indicative of a normal region. The unavailability of fur-
ther patient material has precluded further analysis of
the undeleted region between the two deleted segments.
Another example of the importance of identiﬁcation
of breakpoints is observed in three patientswith complex
phenotypes, including epilepsy (patients A5–A7). Each of
these patients contains microscopically indistinguishable,
interstitial deletions of chromosome 5 at bands q14.2
and q15. However, although all three patients have sei-
zures, there is considerable phenotypic variation, which
is suggestive of underlying mutation differences. The
Mapping 100K data clearly reveal differences among the
three patients (ﬁg. 3 and table 1). Deletions of different
size (7.1, 8.9, and 6.2 Mb) and location were detected,
with a 1.4-Mb shared region of overlap from position
88641040 to 90111353 (ﬁg. 3 and table 1). This region
contains the gene MASS1/VLGR1 (MIM 602851), a
gene implicated in epilepsy (Nakayama et al. 2002). The
ﬂanking deleted regions on either side of the overlap are
6.4 and 4.8 Mb and contain 11 and 9 RefSeq genes,
respectively. The variety of phenotypes observed in these
three patients presumably reﬂects the different gene con-
tent within the individual deletions. Thus, valuable infor-
mation regarding phenotypic variability can be obtained
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Figure 8 Box plots of GSA_CN and GSA_pVal for all patients.
The legend is available in its entirety in the online edition of The Ameri-
can Journal of Human Genetics.
Figure 7 A, Maternal UPD of chromosome 15 of family F1: GeneChip 100K array LOH proﬁles of chromosome 15 in the child, mother,
and father. Note that the child’s and mother’s proﬁles are identical except at the arrowed proximal homozygous region (cen-15p12). The default
window size of 0.5 Mb was used. B, Diagram illustrating the origin of the isodisomic and heterodisomic regions in the child’s chromosome 15
homologues, from a single crossover in the mother’s meiosis I (MI), followed by a meiosis II nondisjunction and postfertilization trisomy rescue
through loss of the paternal homologue. Physical position is shown on the X-axis. The Y-axis shows LOH values from CNAT for three different
patient samples, with comparison of three deletions in chromosome 5 at band q14.2-q15 in patients A5, A6, and A7.
by the more-precise breakpoint determinations obtained
by using the Mapping 100K approach.
The initial cytogenetic analysis of patient A8 identi-
ﬁed a deletion in region 17p11.2-12, which is typically
associated with Smith-Magenis syndrome (SMS [MIM
#182290]). Clinically, however, the patient showed an
unusual phenotype with a nonverbal learning disability,
a ﬁnding inconsistent with this diagnosis (Rourke 1995).
We used the GeneChip Mapping 100K array to identify
a 4.6-Mb deletion (table 1 and ﬁg. 4a) that is ∼4 Mb
distal to the SMS critical region, placing it in bands p12-
13.1. We conﬁrmed this unexpected ﬁnding, using FISH
with BAC clone RP11-601N13, which also showed a
more distal deletion that did not include the SMS critical
region (ﬁg. 4b). The deletion is unique (i.e., not associ-
ated with a classiﬁed syndrome) and contains ∼23 genes.
One of these genes, GAS7 (MIM 603127), a gene in-
volved in neuronal development, could be involved in
the child’s remarkable incongruence in higher cerebral
functioning (Steele et al. 2005).
Identiﬁcation of Anonymous Chromatin Additions
Patients B2–B4 and C2 each contain small, microscop-
ically visible, interstitial or terminal additions of anony-
mous chromatin (table 1). G banding is not useful for
identiﬁcation of small chromosome segments. High-reso-
lution cytogenetic banding analysis failed to identify the
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Figure 9 Box plots of GSA_CN and GSA_pVal for 42 white
reference individuals. The legend is available in its entirety in the online
edition of The American Journal of Human Genetics.
Table 8
Estimation of FPR
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
donor chromosome in all these cases. GeneChip Map-
ping 100K arrays showed duplications of 5.3 (2.5
), 7.4, and 7.7 Mb regions for patients B2, B3, and2.8
B4, respectively (table 1). The abnormalities ranged from
an interstitial, tandem duplication of Xq26-27 (patient
B2) (Solomon et al. 2002) to an interstitial duplication
of 16q12.1-q12.2 inserted into the heterochromatic re-
gion of 16q11 (patient B3) (Ren et al. 2005) and a ter-
minal, tandem duplication of 6p25 (patient B4). Figure
5 illustrates the tandem duplication identiﬁed on chro-
mosome 6 in patient B4. The FISH data derived from a
chromosome 6–speciﬁc probe conﬁrm the identity of the
small additional segment (arrow in ﬁg. 5b).
The abnormality in patient C2 is a derivative of a
balanced, parental, reciprocal translocation. Patient C3
also has an unbalanced reciprocal translocation, but de-
rived de novo. The small duplicated regions in both cases
were partially characterized elsewhere (unpublished data)
by use of MLPA-PCR and FISH. The GeneChip Map-
ping 100K array data from patients C2 and C3 revealed
duplications of 7 and 11 Mb, respectively, and a 4.8-
Mb deletion in patient C3 (table 1). The deletion on
chromosome 9 in patient C2, identiﬁed by MLPA-PCR,
contains the gene MRPL41 and is very close to the telo-
mere, ∼0.7 Mb. On the Mapping 100K arrays, there
are two terminal probes that ﬂank this region (SNP_A-
1692185 and SNP_A-1738565), and they are ∼1 Mb
apart. Mapping 100K data from both of these SNPs
are suggestive of a deletion, as indicated by a copy num-
ber !2 and a negative P value; however, the algorithm,
which uses a 0.5-Mb genome-smoothed average win-
dow, does not identify it as statistically signiﬁcant (data
not shown). The next adjacent Mapping 100K SNP
(SNP_A-1656627), 0.9 Mb away, does not appear to be
deleted. Improvement of the ability to identify small telo-
meric deletions will probably require both further im-
provements to the CNAT algorithm and the addition of
additional markers to telomeric regions, in which SNP
density is typically below the genome average.
Detection of Trisomy
Trisomic cases are typically easy to identify by karyo-
typing—except in certain situations such as spontane-
ous miscarriages, for which nonviable or poorly growing
cultures of placental biopsy specimens are inadequate
for chromosome analysis. By use of the small amount
of starting material required for the GeneChip Mapping
100K approach (250 ng per array), trisomies from these
types of samples are easily identiﬁed (table 1 and ﬁg.
6a). Karyotyping of patient C4 conﬁrms a double tri-
somy of chromosomes 8 (ﬁg. 6b) and 21 (data not shown),
and karyotyping of patient C5 conﬁrms a single trisomy
of chromosome 21 (table 1).
Identiﬁcation of Copy-Neutral Events
Current microscopic methods do not identify copy-
neutral aberrations such as UPD. In addition to the rapid
identiﬁcation of deletions and duplications in clinical
samples shown above, an added beneﬁt of the Mapping
100K arrays is the simultaneous collection of accurate
genotype information on 1100,000 SNPs in a single ex-
periment. This allows for the detection of copy-neutral
events such as UPD, as well as providing valuable infor-
mation on the parental source of the disomy. We ex-
amined two families (F1 and F2), each known to have
a maternal UPD of chromosome 15 causing PWS in the
proband. Since karyotyping and FISH are unable to de-
tect this copy-neutral aberration, these abnormalities
were initially detected using methylation and microsat-
ellite analysis (Slater et al. 1997). The present analysis
with use of Mapping 100K arrays reveals that, in pro-
bands from both families, all genotypes for the 3,032
SNPs on chromosome 15 are consistent with maternal,
not paternal, origin (table 3). In family F2, the genotypes
are 100% identical between mother and child, whereas
they are 63.6% identical between father and child. Only
genotypes that are called in both samples are compared.
In family F1, the child’s genotypes are all consistent with
maternal origin and maternal UPD (table 3). Further-
more, the 87 SNPs (from SNP_A-1713638 to SNP_A-
1708745 [5 Mb]) nearest the centromere in the long arm
are all homozygous in the child; the mother has 21 het-
erozygous SNPs in this region. There are no other ex-
tensive regions of segmental homozygosity distal to this
region in the child. The isodisomic region is clearly ap-
parent in the aligned LOH proﬁles (ﬁg. 7a). This is con-
sistent with isodisomy in the proximal region and het-
erodisomy in the distal region. This is interpreted to be
a consequence of meiosis II nondisjunction after a single
crossover in meiosis I, which has introduced the distal
heterozygous region (ﬁg. 7b). This is followed by post-
zygotic loss of the paternal homologue through trisomy
rescue. This region of isodisomy was not apparent in
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the microsatellite data because of the limited number of
loci ( ) and the locations of informative genotypes.np 14
Discussion
This study describes the application of GeneChip Map-
ping 100K arrays for high-resolution chromosomal an-
alysis in clinical samples. Our approach overcomes sev-
eral hurdles in cytogenetic analysis. First, the small DNA
requirement (250 ng per array) allows rapid and accu-
rate molecular analysis in cases for which cell culture is
problematic or not possible. Second, the increase in reso-
lution allows a more reﬁned analysis, which results in
more-accurate breakpoint determinations, detection of
small deletions and ampliﬁcations, and identiﬁcation of
small segments of unbalanced translocations, thus ob-
viating the need for follow-up tests. Third, unlike array-
based CGH strategies that provide copy-number data
but no genotypes, the Mapping 100K arrays offer both.
This combination enables the detection of copy-neutral
chromosomal aberrations such as UPD and, when pa-
rental DNA is available, can determine the provenance
of the disomic event.
Within the limitations of existing analytical techniques,
inaccurate diagnosis is a rare but potentially serious oc-
currence. It usually occurs as a result of using subop-
timal cell preparations and analytical subjectivity. Cur-
rently, potential misdiagnoses are brought to light only
through checking procedures or when a karyotype is
inconsistent with the phenotype of the patient. This was
observed in patient A8, for whom additional FISH tests
were required to determine the proper diagnosis of the
patient. The reproducibility and therefore consistency
of GeneChip Mapping 100K array data and the ob-
jectivity of the analysis should signiﬁcantly reduce the
chances of reporting a false result.
Because of the high standards for accuracy in clinical
testing, we performed an initial evaluation of the repro-
ducibility of the Mapping 100K approach. Of the 24
samples in the present study, independent replicates were
performed for ﬁve of the samples and showed highly
consistent results, as determined by similar patterns of
copy-number changes and genotype calls (99.99% con-
cordance between replicate samples). The genotyping
accuracy on these arrays is 199.5%, which allows for
high conﬁdence calls (Kennedy et al. 2003). In two in-
dependent families (F1 and F2) in which the affected
child had UPD on chromosome 15, genotype calls were
100% concordant, which conﬁrms the robustness and
accuracy of this technique (ﬁg. 7).
The Mapping 100K technology can detect most but
not all types of abnormalities. Unlike karyotyping, SNP
microarray analysis cannot detect balanced chromosome
rearrangements, such as reciprocal translocations and
inversions. This is also the case for CGH and is the
result of the target preparation method, which includes
fragmentation of the genome before hybridization to
arrayed BACs, cDNAs, or oligonucleotides. Linear infor-
mation is not preserved; thus, only translocations that
result in copy-number change (i.e., unbalanced trans-
locations) will be detected by these methods. It is worth
noting, however, that Mapping 100K analysis would
identify the small proportion of apparently balanced ab-
normalities that, in fact, have subtle deletions and/or
duplications at their breakpoints (Fiegler et al. 2003).
This is particularly relevant for de novo, reciprocal trans-
locations discovered prenatally. Abnormalities that af-
fect only a small proportion of cells (i.e., mosaicism),
would also be expected to present detection problems
for Mapping 100K and CGH technologies. It is notable
that SNP analysis of leukemic patient C1 indicated de-
tection of a deletion that FISH analysis had detected in
81% of cells.
In this study, we used CNAT, a publicly available tool
for determining copy-number changes on SNP arrays
that does have the pairing requirement. CNAT uses a
set of 110 unaffected reference individuals and thus over-
comes the pairing requirement, but it does not account
for experimental variation in the samples being com-
pared (Huang et al. 2004). Recently, another tool has
become available for analyzing copy-number data from
the Mapping 100K arrays: dChipSNP (which uses sig-
niﬁcance curve and clustering of SNP array–based LOH
data) (Janne et al. 2004; Lin et al. 2004). Furthermore,
novel algorithms are currently being developed to ac-
count for experimental variation (Nannya et al. 2005),
and it is likely that additional algorithms will be devel-
oped that will further improve signal-to-noise ratios.
Two recent studies that make use of CGH have re-
ported large-scale CNVs in the normal human genome
(Iafrate et al. 2004; Sebat et al. 2004). The signiﬁcance
of these genome variations is currently unknown (Carter
2004). The identiﬁcation of these types of normal CNVs
was not within the scope of this study; it is likely that
a modiﬁcation to the CNAT algorithm would be re-
quired to detect them. This is because the algorithm
used in our study compares copy-number data from the
test sample with a reference set; the individuals included
in the reference set would be expected to contain normal
CNV. According to the TCAG Genomics Variation da-
tabase (Centre for Applied Genomics), the average size
of a CNV is 400 kb, and, with 91% of the genome
within 100 kb of a SNP on the 100K arrays, it is highly
likely that multiple SNPs would cover each CNV and
would theoretically be detectable.
In conclusion, we evaluated the performance of the
GeneChip Mapping 100K arrays for a series of cases
that reﬂect the typical range of analytical problems con-
fronted in a large diagnostic cytogenetics laboratory.
These cases were chosen because they exemplify the
724 Am. J. Hum. Genet. 77:709–726, 2005
shortcomings of conventional analysis, including lack
of viable samples for chromosome spreads and abnor-
malities that may be too small or too structurally com-
plex to detect by microscopy. We detected all known
chromosomal abnormalities in these samples, as well as
unknown abnormalities in previously uncharacterized
samples. Furthermore, the advantage of obtaining ac-
curate genotype information was clearly demonstrated
in two cases of UPD for which parental genotype in-
formation identiﬁed the origin and mechanism of
the chromosomal aberration. Taken together, the results
across this spectrum of clinical samples suggest that this
single assay has the potential to replace multiple time-
consuming tests currently being performed for clinical
diagnosis.
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Appendix A
Our ASCII ﬁle (online only) contains all of the geno-
type calls for each SNP for all patients used in this study,
as determined by GDAS with a P value cutoff of .05.
The quantitative PCR for patient C1 is shown in table
2. Patient C1 and four unaffected control samples were
assayed twice in triplicate. For probes within the deleted
region, the normalized values for patient C1 were !0.5
(0.21 and 0.23 for BC039725 and ELMO1, respective-
ly), which indicates a deletion. For probes outside the
deleted region, the normalized values for patient C1were
equal to 1.18 and 0.84 for APC exons 5 and 2, respec-
tively (table 3), which indicates no deletion. Box plots
were generated for all of the patients (table 1 and ﬁg.
8) and for 42 white reference individuals (ﬁg. 9). These
42 white reference individuals are part of the 1100 ref-
erence samples used by CNAT; the samples were pur-
chased from the Coriell Institute. Tables 4 and 5 show
the ﬁve-value summary of these box plots (minimum,
lower-quartile, median, upper-quartile, and maximum
values of the distribution) and the SD for each sample,
for both GSA_CN and GSA_pVal metrics. A 95% CI
was calculated by determining 2 SDs from the median
value of the distribution in each sample (tables 6 and
7). Since we know these are true aberrations, we hy-
pothesized that SNPs that fell outside the 95%CI should
represent aberrations, since they are statistically different
from the overall “normal” distribution. For each patient,
the average GSA_CN and GSA_pVal for the described
aberration (table 1) were determined by taking all the
SNPs within the observed deletion or duplication and
computing the average GSA_CN and GSA_pVal (table
7). Many of the aberrations described herein were out-
side the 95% CI calculated for the corresponding sam-
ple; thus, this method could be used to determine thresh-
olds in samples with unknown copy-number changes. For
four of the patients, only the GSA_CN metric “failed”
(i.e., fell within the 95% CI). Three that fell within the
95% CI showed ∼3% deviation from the 95% CI for
either GSA_CN or GSA_pVal metric (data not shown).
The false-negative rate (FNR) could be estimated on the
basis of those aberrations that did not fall outside the
95% CI. On the basis of these data, the FNR is ∼17%
(four patients for whom both GSA_CN and GSA_pVal
“failed” and a total of 23 aberrations tested). Although
this is relatively high, it is probably an overestimate be-
cause of several factors: sample size, size of aberrations,
and sample selection bias. In this study, we investigated
only 17 patients with 23 aberrations. This is a very small
sample set to evaluate FNR and FPR. Although the size
of the aberrations studied herein had a range of 1.3–145.9
Mb, there are many sizes within this range that were not
tested. Additionally, these samples were chosen because
they were typical cytogenetic referral cases and had been
previously characterized by another method. Therefore,
the sample selection was biased. Ideally, a larger, more
comprehensive data set would be needed to evaluate the
FNR and FPR. Finally, by evaluating the number of SNPs
that are outside the 95% CI for the 42 white samples, an
estimate of the FPR was determined as the average per-
centage of SNPs that were outside the 95% CI for either
GSA_CN or GSA_pVal metrics. The FPR was 2.04%–
3.48% (table 8).
Web Resources
The URLs for data presented herein are as follows:
Affymetrix, http://www.affymetrix.com/support/developer/
tools/affytools.affx
Centre for Applied Genomics, http://www.tcag.ca/
Coriell Institute, http://ccr.coriell.org/nigms/
Online Mendelian Inheritance of Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for CFTR exon 24, APC, MLL,
PAH, HNPP, CMT1A, PWS, AS,MASS1/VLGR1, SMS, and
GAS7)
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